Present status of chymopapain and chemonucleolysis.
An analysis of recent events and newly published data on Chymopapain and the technique of Chemonucleolysis including an objective analysis of clinical and basic research as well as the circumstances leading to the FDA curtailment of the use of Chymopapain in the United States, indicate that the drug should be reapproved for investigational use.